Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming

Open access
Schwartz, Brian E., Hofer, Matthias D., Lemieux, Madeleine E., Bauer, Daniel E., Cameron, Michael J., West, Nathan H., Agoston, Elin S., Reynoird, Nicolas, Khochbin, Saadi, Ince, Tan A., Christie, Amanda, Janeway, Katherine A., Vargas, Sara O., Perez-Atayde, Antonio R., Aster, Jon C., Sallan, Stephen E., Kung, Andrew L., Bradner, James E., French, Christopher A.·2011·Cancer Research

Abstract

NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patient-derived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC. Cancer Res; 71(7); 2686–96. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-3513

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 217

Metadata

Authors
Schwartz, B. E., Hofer, M. D., Lemieux, M. E., Bauer, D. E., Cameron, M. J., West, N. H., Agoston, E. S., Reynoird, N., Khochbin, S., Ince, T. A., Christie, A., Janeway, K. A., Vargas, S. O., Perez-Atayde, A. R., Aster, J. C., Sallan, S. E., Kung, A. L., Bradner, J. E., & French, C. A.
Venue
Cancer Research
Published
2011-03-31
Volume
71
Issue
7
Pages
2686-2696
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2029572722
Cited by
217
References
6
FWCI
6.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-3513
The paper
Schwartz, B. E., Hofer, M. D., Lemieux, M. E., Bauer, D. E., Cameron, M. J., West, N. H., Agoston, E. S., Reynoird, N., Khochbin, S., Ince, T. A., Christie, A., Janeway, K. A., Vargas, S. O., Perez-Atayde, A. R., Aster, J. C., Sallan, S. E., Kung, A. L., Bradner, J. E., & French, C. A. (2011). Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-3513

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.